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Clinical evidence for thrombospondin-1 as a relevant suppressor
of liver regeneration
To the Editor:
The most signiﬁcant factor determining morbidity and mortality
following hepatectomy is the ability of the remnant liver to
regenerate. In this context, Hayashi et al. [1] recently reported
on a previously unknown role of thrombospondin-1 (TSP-1) in
liver regeneration (LR). During tissue remodeling, TSP-1 is
released into the pericellular space to regulate cell survival and
extracellular matrix remodeling [2]. A major TSP-1 function is
the conversion of latent TGF-b1 (transforming growth factor-beta
1) to its active form [3]. Based on a mouse model of partial hep-
atectomy, Hayashi et al. [1] demonstrated that TSP-1 was rapidly
released in response to liver resection and triggered TGF-b1 acti-
vation and signal transduction in hepatocytes as a mechanism to
inhibit the proliferative hepatic response [4–5]. Accordingly,
knockdown of TSP-1 expression resulted in a signiﬁcant reduc-
tion of TGF-b1 signaling, which promoted the proliferation of
hepatocytes and accelerated LR [1]. Thus, TSP-1 was proposed
as an inhibitory element and a potential therapeutic target of
LR. We are now able to present the ﬁrst clinical data, which sup-
port the relevance of TSP-1 in LR based on a cohort of metasta-
sized colorectal cancer (mCRC) patients undergoing hepatic
resection of liver metastases.
A total of 66 mCRC patients without preexisting liver disease
were included. Blood was retrieved before surgery (pre OP) and
on day 1 (POD1) or days 5–8 (POD5) after liver resection, and
plasma was prepared with an optimized method [6–7]. Samples
were assayed by ELISA for human TSP-1 (R&D Systems, Minneap-
olis, MN, USA) and TGF-b1 (eBioscience, San Diego, CA, USA). For
statistical analysis, non-parametric tests (Mann–Whitney U test,
Wilcoxon test and Spearman correlation) and the Fisher exact
test were applied.
A signiﬁcant increase in TSP-1 (Fig. 1A) and TGF-b1 was
observed on POD1 (p = 0.007 and p = 0.006, respectively), which
dropped moderately until POD5 (p = 0.016 and p = 0.397). Circu-
lating TSP-1 and TGF-b1 showed a highly signiﬁcant correlation
(k = 0.736, p <0.001). To further investigate whether a high post-
operative release of TSP-1 or TGF-b1 was associated with delayed
LR, we assessed the incidence of postoperative liver dysfunction
(LD), based on the previously deﬁned ‘‘50–50 criteria’’ [8], with
a prothrombin time (PT) <50% and a serum bilirubin (SB) level
>50 lmol/L (>2.9 mg/dl). Our classiﬁcation referred to measure-
ments of any day within the ﬁrst postoperative week to identify
patients with delayed postoperative hepatic recovery. TSP-1 con-
centrations were signiﬁcantly elevated (Fig. 1B) in patients with
LD (median TSP-1 for LD: 98.8 ng/ml; no LD: 44.6 ng/ml,
p = 0.003). Comparably, circulating TGF-b1 tended to be increased
in individuals with LD (median TGF-b1 for LD: 2266 pg/ml; no LD:
1726 pg/ml), but the difference was not statistically signiﬁcant
(p = 0.102). Of note, our analyses were restricted to total TGF-b1
in patient blood since activated TGF-b1 was below ELISA detec-
tion limit. This may explain the lack of association between
TGF-b1 levels and postoperative LD.
To further characterize the potential of TSP-1 to predict post-
operative LD, a ROC analysis was performed (Fig. 1C), revealing
a signiﬁcant predictive value of circulating TSP-1 on POD1 (AUC:
0.870; p = 0.003). A cut-off level of 100 ng/ml TSP-1 on POD1
was deduced to determine the high-risk group for postoperative
LD with 95% speciﬁcity. No statistically signiﬁcant difference in
age and sex distribution or the site of primary tumor, type of
hepatic resection and preoperative liver function parameters
was observed between the TSP-1high individuals (>100 ng/ml
TSP-1) and patients with lower circulating TSP-1 levels on
POD1.
When biochemical markers of postoperative liver function
were compared between these groups, the TSP-1high patients
showed a signiﬁcant elevation in SB (Fig. 1D) and c-glutamyl-
transferase (p <0.001; p = 0.011). Prothrombin time (Fig. 1E)
was found to be signiﬁcantly decreased in TSP-1high patients
(p <0.001). A trend towards elevated alanine and aspartate
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Fig. 1. Association of plasma TSP-1 with parameters of postoperative liver
regeneration. (A) Plasma levels of TSP-1 were determined in mCRC patients
before surgery, on the ﬁrst postoperative day (POD1) and between POD 5–8.
Patients with or without postoperative liver dysfunction (LD) were compared for
circulating TSP-1 by (B) boxplot illustration (without outliers and extreme values;
⁄p <0.05; ⁄⁄p <0.01) and by (C) ROC analysis. The perioperative time course of
median liver function parameters (D) serum bilirubin (SB) and (E) prothrombin
time (PT) was evaluated separately for patients with low (6100 ng/ml) and high
(>100 ng/ml) circulating plasma TSP-1 on POD1.
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aminotransferase levels was found in TSP-1high patients but did
not reach statistical signiﬁcance (p = 0.125 and p = 0.092).
We further assessed the clinical performance of TSP-1high indi-
viduals in terms of morbidity and hospital stay. Only 4 patients
suffered from severe morbidity of grade III, IV or V according to
Dindo et al. [9], which limits the conclusions of the statistical
analysis. However, TSP-1 levels were signiﬁcantly elevated in
patients with severe complications (p = 0.016) and we found a
substantial increase of postoperative severe morbidity from 4%
to 33% in the TSP-1high subgroup (p = 0.053). With respect to hos-
pital stay, a highly signiﬁcant correlation of TSP-1 levels on POD1
with days of postoperative hospitalization was observed
(k = 0.488; p <0.001). In accordance, TSP-1high patients required
a doubled median hospitalization time of 16.5 days as compared
to 8 days for the remaining patients to recover from hepatectomy
(p = 0.011).
In conclusion, these are the ﬁrst clinical data conﬁrming that
TSP-1 negatively correlates with liver regeneration in humans,
which warrants validation in large-scale studies. TSP-1 may
prove a helpful clinical marker to predict LD on the ﬁrst postop-
erative day and to identify high-risk patients for potential com-
plications and suitable interventions.
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